A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro-Reference-Cited by-同舟云学术

A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Published:2015-01-26 Issue:3 Volume:133 Page:440-451
ISSN:0022-3042
Container-title:Journal of Neurochemistry
language:en
Short-container-title:J. Neurochem.

Author:

Coutadeur Séverine¹,Benyamine Hélène¹,Delalonde Laurence¹,de Oliveira Catherine¹,Leblond Bertrand¹,Foucourt Alicia²,Besson Thierry²,Casagrande Anne-Sophie¹,Taverne Thierry¹,Girard Angélique¹,Pando Matthew P.¹,Désiré Laurent¹

Affiliation:

1. Diaxonhit; Paris France

2. Normandie Univ; COBRA; UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS; IRCOF; 1 rue Tesnière; Mont St Aignan Cedex; Paris France

Funder

MESR

LABEX SynOrg

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jnc.13018/fullpdf

Reference46 articles.

1. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease;Augustinack;Acta Neuropathol.,2002

2. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation;Azorsa;BMC Genom,2010

3. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders;Ballatore;Nat. Rev. Neurosci.,2007

4. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases;Becker;J. Biol. Chem.,1998

5. DYRK1A: a potential drug target for multiple down syndrome neuropathologies;Becker;CNS Neurol. Disord. Drug Targets.,2014

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach;International Journal of Molecular Sciences;2023-12-23

2. Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer;Journal of Medicinal Chemistry;2023-11-30

3. Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice;Journal of Cellular and Molecular Medicine;2023-07-06

4. An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease;Neuropharmacology;2023-07

5. Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases;Biochemical Pharmacology;2023-06